MedTrace Logo

Ovarian Hyperstimulation Syndrome and Cabergoline

NCT01569256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-04-04

No results posted yet for this study

Summary

Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome (OHSS).

Conditions

  • Polycystic Ovarian Syndrome
  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Cabergoline

Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days

Sponsors & Collaborators

  • Etlik Zubeyde Hanim Womens' Health and Teaching Hospital

    lead UNKNOWN

Principal Investigators

  • Emine Seda Guvendag Guven, MD · Rize University, Faculty of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
23 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01569256 on ClinicalTrials.gov